Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3100-3102

  Odabasi, Z ^a   Karaalp, A ^a   Cermik, H ^b   Mohr, J ^c   Tigen, E T ^a   Koc, M ^a   Korten, V ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ETIMESGUT MILITARY HOSPITAL   (Turkey)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMPHOTERICIN B DEOXYCHOLATE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; KIDNEY TUBULE DAMAGE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TREATMENT OUTCOME;

ACETYLCYSTEINE; AMPHOTERICIN B; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; APOPTOSIS; KIDNEY; KIDNEY TUBULES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 67649991195     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00001-09     Document Type: Article

References (35)

1. Appenroth, D., K. Winnefeld, H. Schroter, and M. Rost. 1993. Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. J. Appl. Toxicol. 13:189-192.
2. Bakris, G. L., N. Lass, A. O. Gaber, J. D. Jones, and J. C. Burnett, Jr. 1990. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am. J. Physiol. 258:F115-F120.
3. Bates, D. W., L. Su, D. T. Yu, G. M. Chertow, D. L. Seger, D. R. Gomes, E. J. Dasbach, and R. Platt. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32:686-693.
4. Briguori, C., A. Colombo, A. Violante, P. Balestrieri, F. Manganelli, P. Paolo Elia, B. Golia, S. Lepore, G. Riviezzo, P. Scarpato, A. Focaccio, M. Librera, E. Bonizzoni, and B. Ricciardelli. 2004. Standard vs double dose of Nacetylcysteine to prevent contrast agent associated nephrotoxicity. Eur. Heart J. 25:206-211.
5. Briguori, C., F. Manganelli, P. Scarpato, P. P. Elia, B. Golia, G. Riviezzo, S. Lepore, M. Librera, B. Villari, A. Colombo, and B. Ricciardelli. 2002. Acetylcysteine and contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 40:298-303.
6. Bullock, W. E., R. G. Luke, C. E. Nuttall, and D. Bhathena. 1976. Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob. Agents Chemother. 10:555-563.
7. Caillot, D., G. Reny, E. Solary, O. Casasnovas, P. Chavanet, B. Bonnotte, L.Perello, M. Dumas, F. Entezam, and H. Guy. 1994. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J. Antimicrob. Chemother. 33:603-613.
8. Caldicott, W. J., N. K. Hollenberg, and H. L. Abrams. 1970. Characteristics of response of renal vascular bed to contrast media. Evidence for vasoconstriction induced by renin-angiotensin system. Investig. Radiol. 5:539-547.
9. Carrigan Harrell, C., and L. Hanf-Kristufek. 2001. Comparison of nephrotoxicity of amphotericin B products. Clin. Infect. Dis. 32:990-991.
10. Eriksson, U., B. Seifert, and A. Schaffner. 2001. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322:579-582.
11. Fanos, V., and L. Cataldi. 2000. Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12:463-470.
12. Feldman, L., S. Efrati, V. Dishy, L. Katchko, S. Berman, M. Averbukh, M. Aladjem, Z. Averbukh, and J. Weissgarten. 2005. N-Acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol. 99: p23-p27.
13. Fishbane, S. 2008. N-Acetylcysteine in the prevention of contrast-induced nephropathy. Clin. J. Am. Soc. Nephrol. 3:281-287.
14. Girmenia, C., G. Gentile, A. Micozzi, and P. Martino. 2001. Nephrotoxicity of amphotericin B desoxycholate. Clin. Infect. Dis. 33:915-916.
15. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, R. M. Alfaro, C. King, S. C. Piscitelli, and T. J. Walsh. 2003. Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob. Agents Chemother. 47:3917-3925.
16. Harbarth, S., S. L. Pestotnik, J. F. Lloyd, J. P. Burke, and M. H. Samore. 2001. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. 111:528-534.
17. Herbrecht, R., S. Natarajan-Ame, Y. Nivoix, and V. Letscher-Bru. 2003. The lipid formulations of amphotericin B. Expert Opin. Pharmacother. 4:1277-1287.
18. Imhof, A., R. B. Walter, and A. Schaffner. 2003. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. 36:943-951.
19. Moreau, P., N. Milpied, N. Fayette, J. F. Ramee, and J. L. Harousseau. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30:535-541.
20. Nitescu, N., S. E. Ricksten, N. Marcussen, B. Haraldsson, U. Nilsson, S. Basu, and G. Guron. 2006. N-Acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol. Dial. Transplant. 21: 1240-1247.
21. Nucci, M., M. Loureiro, F. Silveira, A. R. Casali, L. F. Bouzas, E. Velasco, N. Spector, and W. Pulcheri. 1999. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob. Agents Chemother. 43:1445-1448.
22. Odabasi, Z., A. Karaalp, H. Cermik, J. Mohr, O. Ergonul, Z. Agalar, B. Sumer, L. Mulazimoglu, and V. Korten. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1100, p. 22. American Society for Microbiology, Washington, DC.
23. Olson, J. A., J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
24. Persson, P. B., and M. Tepel. 2006. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int. Suppl. 2006:S8-S10.
25. Schoffski, P., M. Freund, R. Wunder, D. Petersen, C. H. Kohne, H. Hecker, U. Schubert, and A. Ganser. 1998. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 317:379-384.
26. Solomon, R. 1998. Contrast-medium-induced acute renal failure. Kidney Int. 53:230-242.
27. Sorkine, P., H. Nagar, A. Weinbroum, A. Setton, E. Israitel, A. Scarlatt, A. Silbiger, V. Rudick, Y. Kluger, and P. Halpern. 1996. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit. Care Med. 24:1311-1315.
28. Tepel, M. 2003. Acetylcysteine for the prevention of radiocontrast-induced nephropathy. Minerva Cardioangiol. 51:525-530.
29. Tepel, M. 2006. Preventing nephropathy induced by contrast medium. N. Engl. J. Med. 354:1853-1855.
30. Tepel, M., M. van der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek. 2000. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343:180-184.
31. van den Berk, G., S. Tonino, C. de Fijter, W. Smit, and M. J. Schultz. 2005. Bench-to-bedside review: preventive measures for contrast-induced nephropathy in critically ill patients. Crit. Care 9:361-370.
32. Varlam, D. E., M. M. Siddiq, L. A. Parton, and H. Russmann. 2001. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob. Agents Chemother. 45:679-685.
33. Weisberg, L. S., P. B. Kurnik, and B. R. Kurnik. 1994. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 45:259-265.
34. Wingard, J. R., P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, R. Bowden, E. Anaissie, J. Hiemenz, and J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1402-1407.
35. Wong-Beringer, A., R. A. Jacobs, and B. J. Guglielmo. 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:603-618.